Transgene (XPAR:TNG) Treasury Stock : €0.00 Mil (As of Jun. 2024)

View and export this data going back to 1998. Start your Free Trial

What is Transgene Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Transgene's treasury stock for the quarter that ended in Jun. 2024 was €0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Transgene Treasury Stock Historical Data

The historical data trend for Transgene's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Treasury Stock Chart

Transgene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Treasury Stock

Get a 7-Day Free Trial

Transgene Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Transgene Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Transgene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (XPAR:TNG) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

0OCQ:UK TGNA:Germany

Address

400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.

Transgene Headlines

No Headlines